Cargando…
Immunotherapy for head and neck squamous cell carcinoma
Over the past years immuno-oncology has evolved and become a novel promising strategy for cancer therapy. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been rece...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923082/ https://www.ncbi.nlm.nih.gov/pubmed/27429658 http://dx.doi.org/10.1007/s12254-016-0270-8 |
_version_ | 1782439679479513088 |
---|---|
author | Fuereder, Thorsten |
author_facet | Fuereder, Thorsten |
author_sort | Fuereder, Thorsten |
collection | PubMed |
description | Over the past years immuno-oncology has evolved and become a novel promising strategy for cancer therapy. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been recently approved for the treatment of various malignancies and are currently being investigated in clinical phase III trials for head and neck squamous cell carcinoma (HNSCC). Data available from these trials indicate substantial activity accompanied by a favorable safety and toxicity profile in this patient population. This review article focuses on the molecular background, gives an overview of current clinical data of checkpoint inhibitors in HNSCC, and points out future challenges such as the need for appropriate biomarkers for these novel compounds. |
format | Online Article Text |
id | pubmed-4923082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-49230822016-07-13 Immunotherapy for head and neck squamous cell carcinoma Fuereder, Thorsten Memo Short Review Over the past years immuno-oncology has evolved and become a novel promising strategy for cancer therapy. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been recently approved for the treatment of various malignancies and are currently being investigated in clinical phase III trials for head and neck squamous cell carcinoma (HNSCC). Data available from these trials indicate substantial activity accompanied by a favorable safety and toxicity profile in this patient population. This review article focuses on the molecular background, gives an overview of current clinical data of checkpoint inhibitors in HNSCC, and points out future challenges such as the need for appropriate biomarkers for these novel compounds. Springer Vienna 2016-06-20 2016 /pmc/articles/PMC4923082/ /pubmed/27429658 http://dx.doi.org/10.1007/s12254-016-0270-8 Text en © The Author(s) 2016 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Short Review Fuereder, Thorsten Immunotherapy for head and neck squamous cell carcinoma |
title | Immunotherapy for head and neck squamous cell carcinoma |
title_full | Immunotherapy for head and neck squamous cell carcinoma |
title_fullStr | Immunotherapy for head and neck squamous cell carcinoma |
title_full_unstemmed | Immunotherapy for head and neck squamous cell carcinoma |
title_short | Immunotherapy for head and neck squamous cell carcinoma |
title_sort | immunotherapy for head and neck squamous cell carcinoma |
topic | Short Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923082/ https://www.ncbi.nlm.nih.gov/pubmed/27429658 http://dx.doi.org/10.1007/s12254-016-0270-8 |
work_keys_str_mv | AT fuerederthorsten immunotherapyforheadandnecksquamouscellcarcinoma |